Be a medicine innovator The META team has spent 7 years developing the “Modulated Immunometabolic Pathway Strategy”, a revolutionary approach to treating self-infection diseases. This breakthrough therapy provides a safer, more effective, and novel way of fighting such diseases, greatly enhancing patient outcomes.
On March 2-3, the two-day 2023 China Innovation and Entrepreneurship Investment Conference achievement release ceremony and the Greater Bay Area Science and Technology Conference were successfully held at the Shenzhen Futian Convention and Exhibition Center.
The conference, themed “Smart Innovations in China: Illuminating Dreams,” brought together more than 120 experts, scholars, industry leaders, representatives from 9+2 cities, and investment institutions from various fields. Through a combination of online and offline interactions, they explored cutting-edge academic achievements and development trends in areas such as sensors, nanotechnology, artificial intelligence, healthcare monitoring, and AI robotics. This event injected new energy into industrial upgrading and economic growth.
Certainly! The translation of the provided text to English is as follows:
“Wang Jinzhan, Member of the Party Group and Secretary of the Secretariat of the China Association for Science and Technology (CAST); Cheng Hongbo, Secretary of the Party Group and Vice Chairman of the Guangdong Association for Science and Technology (GAST); and Wang Qiang, Member of the Standing Committee of the Shenzhen Municipal Party Committee and Minister of the United Front Work Department, attended the main forum and delivered speeches.
Also present at the event were Song Jun, Vice Chairman of the China Technology Development Foundation, former Member of the Party Group and Secretary of the Secretariat of CAST; Zhang Qing, Director of the Enterprise Innovation Service Center of CAST; Gao Chunbo, Deputy Director of the Enterprise Innovation Service Center of CAST; Hua Xuchu, Member of the Party Group of GAST; Liao Junwen, President of the Shenzhen Association for Science and Technology (SAST), Special Invited Vice Chairman of the China Industry-University-Research Cooperation Promotion Association, Vice Chairman of the 4th Shenzhen Municipal Committee of the Chinese People’s Political Consultative Conference (CPPCC), and former Minister of the United Front Work Department; and Lin Xiang, Secretary of the Party Group and Deputy Chairman of SAST. These leaders and experts attended the event.
META stood out among several high-quality projects at this conference and was awarded the ‘Top 100’ by the conference organizing committee. This recognition reflects the acknowledgment from numerous industry experts, judges, and professional institutions, highlighting MetaNovas Biotech’s immense development potential.
On December 28, 2023, the 13th CCTV Financial Forum in Hong Kong, with the theme of ‘Technology Innovation: Activating New Drivers for Economic Development’, was held in Hong Kong. The forum aimed to facilitate discussions and exchanges on how technology innovation can empower high-quality economic development.
Hong Kong Special Administrative Region Chief Executive John Lee, National Committee Member of the Chinese People’s Political Consultative Conference (CPPCC) and Chairman and Chief Editor of Hong Kong Ta Kung Wen Wei Media Group, Lee Tai-hung, and Peng Jianming, Member of the Editorial Board Meeting and General Manager of the Central Radio and Television Station, were among the participants in the forum and delivered speeches.
Dr. Ke Xu, Co-founder and CEO of META Pharmaceuticals, was also invited to participate in the forum. During the dialogue session, Dr. Xu shared META’s achievements in utilizing artificial intelligence for biomedical research and development. He explained that META is a company focused on developing original drugs for autoimmune diseases, metabolic disorders, and rare diseases. Dr. Xu highlighted that the company has made breakthroughs in chronic disease treatment by regulating the metabolic vitality of immune cells to achieve immune system function modulation.
Dr. Ke Xu, in an interview after the forum, emphasized that the company’s use of AI and machine learning technologies can significantly enhance the efficiency of drug discovery and accelerate the progression of drugs into clinical trials. He also expressed the hope for better integration of innovative AI applications, enabling META to contribute to First-in-class original drugs and continue exploring and benefiting patients in the field of biomedicine.
On December 28, the Sixth Greater Bay Area Biotechnology Innovation Competition awards ceremony for the Top 50 Innovative Biotechnology Enterprises was held with great fanfare in Nansha, Guangzhou. The event was organized by the China Innovation Industry Research Institute, hosted by Guangdong Medical Valley, and co-organized by Haitong Securities. Simultaneously, a Biotechnology Innovation Development Summit was held, aiming to bring together experts and investment professionals from the biopharmaceutical industry, discover outstanding players in the biotechnology sector, and explore collaborative innovation for industry development.
Shu Yuan, Dean of the China Innovation Industry Research Institute; Yan Zhen, Member of the Party Group and Deputy Director of the Guangdong Provincial Drug Administration; Sheng Nanfang, former Director of the China Southern Talent Market and former Vice President of the Guangdong Talent Exchange Association; Tan Hong, Chief Economist of the Guangzhou Development and Reform Commission; Xie Wei, Deputy Secretary of the Party Working Committee of Nansha Development Zone in Guangzhou; Wang Houhua, Deputy Director of the Guangdong Productivity Promotion Center; and Professor Lin Xinhua, Executive Dean of the Precision Medicine Research Institute of the Greater Bay Area, were among the experts who attended the ceremony.
After visits and screenings by the judging panel and investors, META successfully made it to the Top 50 Innovative Biotechnology Enterprises list in the Greater Bay Area and was awarded the title of Emerging Enterprise. This recognition reflects the high regard from numerous professionals for META’s achievements.
Recently, Shenzhen Moyuan Biotechnology Co., Ltd (hereinafter referred to as “META Pharmaceuticals”) has won a number of competitions.
On November 23rd, the 12th China Innovation and Entrepreneurship Competition Biomedicine National Competition, jointly organized by the Ministry of Science and Technology (MOST), the Ministry of Finance (MOF), the Ministry of Education (MOE), the Central Internet Information Office (CIIO), and the All-China Federation of Industry and Commerce (ACFIC), commenced in Taizhou. Xu Yi, the head of relevant institutions directly under the Ministry of Science and Technology, Zhang Xinmin, the director of China Biotechnology Development Center (CBDC), Zhu Lifan, the secretary of Taizhou Municipal Party Committee, as well as responsible comrades from relevant departments of CBDC, the Taizhou Development and Reform Commission (DRC), the Taizhou Science and Technology Bureau (TSTB), and the Taizhou Pharmaceutical Hi-Tech Zone Administrative Committee (TPZAC), participated in the opening ceremony.
After the district and city competitions, META Pharmaceuticals was selected as a finalist in the National Biopharmaceutical Competition for its application and development of immunometabolic strategies on small molecule drugs for various chronic diseases. The company finally won the title of “Excellent Enterprise” among the 324 excellent biopharmaceutical enterprises in the National Competition. Dr. Ke Xu, co-founder and CEO of META Pharmaceuticals, represented the company to give a live defense and receive the award on the stage.
2.META Pharmaceuticals was awarded “Excellence Award” in the Grand Final of 2023 Golden Panda Global Innovation and Entrepreneurship Competition
On November 17, 2023, the Golden Panda Global Innovation & Entrepreneurship Competition Grand Final was successfully held in the Chengdu Hi-Tech Zone. The event was hosted by the Chengdu Municipal People’s Government and organized by the Chengdu Hi-Tech Zone Administrative Committee. The competition drew a total of 2,085 project applications, and after 10 domestic and international field competitions, 46 projects advanced to the finals.
After a rigorous selection process, Dr. Anjin Xianyu, Co-Founder and CTO of META Pharmaceuticals, represented the company in winning the Excellence Award and the corresponding bonus. The award was received on behalf of the company for their research project titled “Research and Development of National Class I Innovative Immunosuppressive Drugs Based on Immuno-metabolism Strategies”. This project stood out among many others in the field of cutting-edge biomedical science and technology.
3.META Pharmaceuticals Won the Third Prize in China Huaihai High-level Talents Entrepreneurship Competition
Recently, the first China Huaihai High-level Talents Entrepreneurship Competition and Xuzhou Economic Development Zone High-level Talents Innovation and Entrepreneurship Competition for Biomedical Health were successfully held in Shenzhen. More than 30 projects, led by academicians from overseas developed countries, national high-level talents, and teams, applied for the competition. META Pharmaceuticals, among several outstanding enterprises, achieved a top 6 ranking in the project, winning the third prize and receiving the corresponding bonus reward.
The fact that META Pharmaceuticals was able to enter and win several national competitions over the past 2 years reflects the recognition by industry experts of META Pharmaceuticals’ innovative ability and development potential. META will also accelerate the R&D process, hoping to contribute to the development of biomedicine.
